Vargas Maria, Buonanno Pasquale, Iacovazzo Carmine, Servillo Giuseppe
Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
Resuscitation. 2019 Mar;136:54-60. doi: 10.1016/j.resuscitation.2019.01.016. Epub 2019 Jan 24.
To evaluate the effectiveness of epinephrine, compared with control treatments, on survival at admission, ROSC, survival at discharge, and a favorable neurologic outcome in adult patients during OHCA.
MEDLINE and PubMed from inception to August 2018.
Randomized controlled trials (RCTs) on adult patients after OHCA treated with epinephrine versus controls.
Independent, double-data extraction; risk of bias assessment with Cochrane Collaboration's criteria.
15 RCTs representing 20 716 OHCA adult patients. Epinephrine, compared with all pooled treatments, was associated with a better survival rate to hospital discharge (RR: 1.16, 95% CI: 1.00-1.35) and a favorable neurologic outcome (RR: 1.24, 95% CI: 1.04-1.48). No difference was found in survival to hospital admission (RR: 1.02, 95% CI: 0.75-1.38) and ROSC when comparing epinephrine with all pooled treatments (RR: 1.13, 95% CI: 0.84-1.53). When epinephrine was compared with a placebo/no drugs, survival to hospital discharge (RR: 1.34, 95% CI: 1.08-1.67), ROSC (RR: 2.03, 95% CI: 1.18-3.51) and survival to hospital admission (RR: 2.04, 95% CI: 1.22-3.43) were increased, but there was not a favorable neurologic outcome (RR: 1.22, 95% CI: 0.99-1.51).
In OHCA, standard or high doses of epinephrine should be used because they improved survival to hospital discharge and resulted in a meaningful clinical outcome. There was also a clear advantage of using epinephrine over a placebo or no drugs in the considered outcomes.
评估肾上腺素与对照治疗相比,对成年院外心脏骤停(OHCA)患者入院时的生存率、恢复自主循环(ROSC)、出院时的生存率以及良好神经功能结局的有效性。
从创刊至2018年8月的MEDLINE和PubMed。
关于OHCA成年患者接受肾上腺素治疗与对照治疗的随机对照试验(RCT)。
独立的双数据提取;采用Cochrane协作网标准进行偏倚风险评估。
15项RCT,共纳入20716例OHCA成年患者。与所有汇总治疗相比,肾上腺素与更高的出院生存率(风险比[RR]:1.16,95%置信区间[CI]:1.00 - 1.35)和良好的神经功能结局相关(RR:1.24,95% CI:1.04 - 1.48)。在比较肾上腺素与所有汇总治疗时,入院生存率(RR:1.02,95% CI:0.75 - 1.38)和ROSC未发现差异(RR:1.13,95% CI:0.84 - 1.53)。当将肾上腺素与安慰剂/无药物比较时,出院生存率(RR:1.34,95% CI:1.08 - 1.67)、ROSC(RR:2.03,95% CI:1.18 - 3.51)和入院生存率(RR:2.04,95% CI:1.22 - 3.43)均有所提高,但未观察到良好的神经功能结局(RR:1.22,95% CI:0.99 - 1.51)。
在OHCA中,应使用标准剂量或高剂量肾上腺素,因为其可提高出院生存率并产生有意义的临床结局。在所考虑的结局方面,使用肾上腺素也明显优于安慰剂或无药物治疗。